Newsfeeds - Spark Newswire

2 minute read

News

Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Today, 12:12 PM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the nomination of EDP-235, its lead

ENTA

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 12:12 PM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 12:12 PM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

6 minute read

14 Biotech Stocks To Watch Over The Next 6 Months

By Shanthi Rexaline

Today, 12:12 PM

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.

AERI

4 minute read

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen’s Migraine Drug Approved In Japan, Liver Congress Gets Underway

By Shanthi Rexaline

Today, 12:12 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22)

ACET

2 minute read

Enanta Pharmaceuticals Reported New Preclinical Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at EASL International Liver Congress; CEO Said Data Strongly Support the Continued Development of EDP-721

By Charles Gross

Today, 12:12 PM

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today reported new preclinical data for EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for HBV.

ENTA

1 minute read

Uncategorized

Enanta’s EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA

By Vandana Singh

Today, 12:12 PM

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study…

ENTA

32 minute read

Uncategorized

Earnings Scheduled For May 6, 2021

By Benzinga Insights

Today, 12:12 PM

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

AAOI